DAFTAR PUSTAKA

1. Riaz K, Ahmed A, Talavera F, Ali YS, Hypertensive Heart Disease. Medscape reference
drug,
disease
and
procedure.
2011
available
at
http://emedicine.medscape.com/article/162449-overview last update 29 mei 2011
2. Diamond JA, PhillipsRA. Hypertensive Heart Disease. Hypertens Res Vol. 28, No. 3
(2005). On International journal of obesity. Hypertension research available at
http://www.nature.com/hr/journal/v28/n3/abs/hr200525a.html last update 29 mei 2011
3. Sudoya AW, Setoyohadi B, Alwi I, Simadibrata M, Setiati S. Buku ajar ilmu penyakit
dalam jilid III edisi 4; Panggambean MM. penyakit jantung hipertensi. Pusat penerbit
ilmu penyakit dalam Fakultas Kedokteran Universitas Indonesia.2006; 1639-1640
4. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality--results from the
Framingham Study. Cardiology. 1992;81(4-5):291-8.
5. Yamasaki N, Kitaoka H, Matsumura Y, et al. Heart failure in the elderly. Intern Med.
May 2003;42(5):383-8.
6. Deschepper CF, Boutin-Ganache I, Zahabi A, Jiang Z: In search of cardiovascular
candidate genes: interactions between phenotypes and genotypes. Hypertension 2002;
39:332336.
7. Molkentin JD, Lu JR, Antos CL, et al: A calcineurin-dependent transcriptional pathway
for cardiac hypertrophy. Cell 1998; 93: 215228.
8. Hsueh WA, Law RE, Do YS: Integrins, adhesion, and cardiac remodeling. Hypertension
1998; 31: 176180.
9. Schunkert H, Jahn L, Izumo S, Apstein CS, Lorell BH:Localization and regulation of cfos and c-jun protooncogene induction by systolic wall stress in normal and
hypertrophied rat hearts. Proc Natl Acad Sci U SA 1991; 88: 11480 11484.
10. Molkentin JD: Calcineurin-NFAT signaling regulates the cardiac hypertrophic response
in coordination with the MAPKs. Cardiovasc Res 2004; 63: 467475.
11. Chen MS, Xu FP, Wang YZ, et al: Statins initiated after hypertrophy inhibit oxidative
stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 2004; 37:
889896.
12. Li YY, McTiernan CF, Feldman AM: Interplay of matrix metalloproteinases, tissue
inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Cardiovasc Res 2000; 46: 214224.
13. PolyakovaV,HeinS,KostinS,ZiegelhoefferT,SchaperJ:Matrixmetalloproteinasesandtheirti
ssue inhibitors in pressure- overloaded human myocardium during heart failure
progression. J Am Coll Cardiol 2004; 44: 16091618.
14. Jones RC, Francis GS, Lauer MS: Predictors of mortality in patients with heart failure
and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll
Cardiol 2004; 44: 10251029.
15. Bonow RO, Udelson JE: Left ventricular diastolic dysfunction as a cause of congestive
heart failure: mechanisms and management. Ann Intern Med 1992; 117: 502510.
16. BrutsaertDL,SysSU,GillebertTC:Diastolicfailure:pathophysiologyandtherapeuticimplicati
ons.J Am Coll Cardiol 1993; 22: 318325 [published erratum appears in J Am Coll
Cardiol 1993; 22: 1272].